18F Flutemetamol amyloid-beta PET imaging compared with [ 11C]PIB across the spectrum of Alzheimer's disease

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 2, 2014, Pages 290-300

  Hatashita, Shizuo ^a   Yamasaki, Hidetomo ^a   Suzuki, Yutaka ^a   Tanaka, Kumiko ^a   Wakebe, Daichi ^a   Hayakawa, Hideki ^a  

^a Shonan Atsugi Hospital   (Japan)

Author keywords

Alzheimer's disease; Amyloid beta (A ); Amyloid imaging; PET

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; FLUTEMETAMOL F 18; PITTSBURGH COMPOUND B; ANILINE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; DIAGNOSTIC AGENT; FLUTEMETAMOL; N METHYL 2 (4' METHYLAMINOPHENYL) 6 HYDROXYBENZOTHIAZOLE; N-METHYL-2-(4'-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE; RADIOPHARMACEUTICAL AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALZHEIMER DISEASE; ANTERIOR CINGULATE; ANTERIOR COMMISSURE; ARTICLE; CLINICAL DEMENTIA RATING; COGNITION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG UPTAKE; FEMALE; FRONTAL CORTEX; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL CORTEX; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRECUNEUS; SENSORIMOTOR CORTEX; TEMPORAL CORTEX; TREATMENT RESPONSE; CASE CONTROL STUDY; COMPARATIVE STUDY; EVALUATION STUDY; SCINTISCANNING;

ADULT; ALZHEIMER DISEASE; ANILINE COMPOUNDS; BENZOTHIAZOLES; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84897911084     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2564-y     Document Type: Article

References (24)

1. McKhann G, Drachman DA, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
2. Kazee AM, Eskin TA, Lapham LW, Gabriel KR, McDaniel KD, Hamill RW. Clinicopathologic correlates in Alzheimer disease: assessment of clinical and pathologic diagnostic criteria. Alzheimer Dis Assoc Disord 1993;7:152-64.
3. Jack Jr CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:257-62.
4. Mathis CA, Wang Y, Holt DP, Huang GF, Debnath ML, Klunk WE. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740-54.
5. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer' disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19.
6. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in human using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005;25: 1528-47.
7. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131:1630-45.
8. Hatashita S, Yamasaki H. Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging. J Alzheimers Dis 2010;21:995-1003.
9. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011;305:275-83.
10. Brthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011;10:424-35.
11. Cselenyi Z, Jönhagen ME, Forsberg A, Halldin C, Julin P, Schou M, et al. Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand. J Nucl Med 2012;53:415-24.
12. Neilssen N, Van Laere K, Thurfiell L, Owenius R, Vandenbulcke M, Koole M, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 2009;50:1251-9.
13. Vandenberghe R Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment A phase 2 trial. Ann Neurol 2010;68:319-29.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
15. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-4.
16. Wechsler DA. Wechsler memory scale-revised. New York: Psychological Corporation; 1987.
17. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's Association. Alzheimers Dement 2011;7:263-9.
18. Albert MS, DeKosky ST, Diskson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270-9.
19. Smith A, Buckley C, Sherwin P, Heurling K, Ikonomovic M, Mathis C, et al. Evaluation of the histopathology burden underlying [18F]flutemetamol PET imaging (abstract). Human Amyloid Imaging 2013;7:32.
20. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006;66: 1837-44.
21. Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol 2011;68(11):1404-11.
22. Hatashita S, Yamasaki H. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction. PLoS One 2013;8(6):e66877. doi:10.1371/journal.pone.0066877.
23. Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O'Keefe G, et al. Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012;39:983-9.
24. Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, et al. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia. J Nucl Med 2013;54:880-6.